INSIGHTS ON DRUG DEVELOPMENT

• Explore Alternative Analytical Methods To Solve Process Challenges

  Successful and rapid analytical method development plays a key role in ensuring the development of robust processes to produce high-quality products. 

• How Can Outsourcing Buffer Preparation Help Meet The Urgent Need For A SARS-CoV-2 Vaccine?

  As numerous therapeutic drug and vaccine candidates make their way through human clinical trials, companies are already planning for how to manufacture any successful molecule on a global scale. In this planning, the preparation of process liquids and buffers should be considered.

• The Role Of CDMOs In Cell And Gene Therapy Process Development

  This article highlights areas where CDMOs can help companies get started in CGT manufacturing. We also discuss when to engage with CDMOs to maximize commercial and clinical success.

• Developing A Scalable Process For Adenovirus Manufacturing

  To address the growing need for speed and efficiency in viral vector manufacturing, Cytiva developed a process for adenovirus manufacturing that not only meets regulatory requirements but is also scalable.

• Demystifying Highly Potent API And Cytotoxic Drug Products

  Capturing the right information early demystifies the development process, especially for drugs with HPAPI components. Gathering, organizing, and understanding critical risk data related to HPAPIs and cytotoxic drugs ensures appropriate controls are defined from concept to clinical batch manufacturing to commercial-scale manufacturing. 

• mRNA - The Vaccine Technology Explained In Short

  With two mRNA-based COVID-19 vaccines coming to market, this innovative platform is delivering on its promise of a safer, faster, more efficacious approach to vaccine manufacturing. mRNA has the potential to revolutionize the vaccine industry and hold a promising pipeline ranging from cancer application to indications with unmet needs such as HIV or Zika. Watch this brief video and explore the science behind mRNA vaccines.

• 3 Ways To Mitigate Data Manipulation Risk In Drug Development

  A critical output of the drug development process, besides the compound itself, is data. We highlight specific actions to mitigate your organization’s risk of data manipulation and three key steps in tackling this problem.

• Delivering Macromolecules: Challenges Associated With The Delivery Of Biologic Drugs

  Developers need to look beyond the formulation of a stable drug all the way to patient compliance. Numerous pitfalls exist along the journey to bring a biologic combination product to market. This integrated solutions program can help you simplify the journey.

• Debunking Myths And Misconceptions About Softgels

  Here, we take a look at some common myths about softgels and explore why drug developers may want to reconsider their go-to delivery methods.